Study of FK463 for the Treatment of Invasive Aspergillosis
NCT ID: NCT00036166
Last Updated: 2018-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
326 participants
INTERVENTIONAL
1999-01-29
2002-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
NCT00036179
Micafungin Salvage Mono-therapy in Invasive Aspergillosis
NCT00376337
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
NCT04876716
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
NCT00076869
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
NCT00047827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FK463
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Has bronchopulmonary aspergillosis, aspergillomas, sinus aspergillosis or external otitis but does not have histologic evidence of tissue invasion
* Has life-expectancy judged to be less than 5 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Univ.-Klinik
Graz, , Austria
Krankenhaus Elisabethinen Linz
Linz, , Austria
Hopital Henri Mondor, Service d'Hematologie Clinique
Créteil, , France
Hotel Dieu, Service d'Hematologie
Nantes, , France
Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle
Paris, , France
Hopital Necker Enfants Malades, Service d'Hematologie
Paris, , France
Johann Wolfgang Goethe Universitat, Medizinische Klinik III
Frankfurt, , Germany
Westpfalz Krankehaus
Kaiserslautern, , Germany
Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie
Leipzig, , Germany
Klinikum der Stadt, Medizinische Klinik A
Ludwigshafen, , Germany
Uniklinik Mainz
Mainz, , Germany
LMU Munchen, Hamatopoetische Zell - Transplantation
München, , Germany
Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie
Würzburg, , Germany
Nationale Institute for Cancer Research
Genova, , Italy
Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera
Milan, , Italy
Institute of Haematology and Blood Transfusion
Warsaw, , Poland
Hospital Clinic I provencial, Servicio Enfermadades Infecciosas
Barcelona, , Spain
Hospital Gregorio Maranon, Servicio de Enfermadades Infecciosas
Madrid, , Spain
Hospital Doce de Octubre, Servicio de Microbiologia y Enfermadades Infecciosas
Madrid, , Spain
Huddinge University Hospital, Dept. of Transplantation Surgery/Immunology
Huddinge, , Sweden
Royal Free Hospital, Dept. of Haematological Oncology
London, , United Kingdom
Christie Hospital NHS Trust
Manchester, , United Kingdom
Royal Marsden Hospital
Sutton Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006 Nov;53(5):337-49. doi: 10.1016/j.jinf.2006.03.003. Epub 2006 May 6.
Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdiere M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2009 Feb;11(1):89-93. doi: 10.1111/j.1399-3062.2008.00349.x. Epub 2008 Oct 8.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
98-0-046
Identifier Type: OTHER
Identifier Source: secondary_id
FG463-21-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.